69
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Glioblastoma cell cultures in vitro are frequently used for investigations on the biology of tumors or new therapeutic approaches. Recent reports have emphasized the importance of cell culture type for maintenance of tumor original features. Nevertheless, the ability of GBM cells to preserve EGFR overdosage in vitro remains controversial. Our experimental approach was based on quantitative analysis of EGFR gene dosage in vitro both at DNA and mRNA level. Real-time PCR data were verified with a FISH method allowing for a distinction between EGFR amplification and polysomy 7. We demonstrated that EGFR amplification accompanied by EGFRwt overexpression was maintained in spheroids, but these phenomena were gradually lost in adherent culture. We noticed a rapid decrease of EGFR overdosage already at the initial stage of cell culture establishment. In contrast to EGFR amplification, the maintenance of polysomy 7 resulted in EGFR locus gain and stabilization even in long-term adherent culture in serum presence. Surprisingly, the EGFRwt expression pattern did not reflect the latter phenomenon and we observed no overexpression of the tested gene. Moreover, quantitative analysis demonstrated that expression of the truncated variant of receptor— EGFRvIII was preserved in GBM-derived spheroids at a level comparable to the initial tumor tissue. Our findings are especially important in the light of research using glioblastoma culture as the experimental model for testing novel EGFR-targeted therapeutics in vitro, with special emphasis on the most common mutated form of receptor—EGFRvIII.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: found

          Genetic pathways to primary and secondary glioblastoma.

          Glioblastoma is the most frequent and most malignant human brain tumor. The prognosis remains very poor, with most patients dying within 1 year after diagnosis. Primary and secondary glioblastoma constitute distinct disease subtypes, affecting patients of different age and developing through different genetic pathways. The majority of cases (>90%) are primary glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion. They affect mainly the elderly and are genetically characterized by loss of heterozygosity 10q (70% of cases), EGFR amplification (36%), p16(INK4a) deletion (31%), and PTEN mutations (25%). Secondary glioblastomas develop through progression from low-grade diffuse astrocytoma or anaplastic astrocytoma and manifest in younger patients. In the pathway to secondary glioblastoma, TP53 mutations are the most frequent and earliest detectable genetic alteration, already present in 60% of precursor low-grade astrocytomas. The mutation pattern is characterized by frequent G:C-->A:T mutations at CpG sites. During progression to glioblastoma, additional mutations accumulate, including loss of heterozygosity 10q25-qter ( approximately 70%), which is the most frequent genetic alteration in both primary and secondary glioblastomas. Primary and secondary glioblastomas also differ significantly in their pattern of promoter methylation and in expression profiles at RNA and protein levels. This has significant implications, particularly for the development of novel, targeted therapies, as discussed in this review.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity.

            Glioblastoma, the most aggressive cerebral tumor, is invariably lethal. Glioblastoma cells express several genes typical of normal neural stem cells. One of them, SOX2, is a master gene involved in sustaining self-renewal of several stem cells, in particular neural stem cells. To investigate its role in the aberrant growth of glioblastoma, we silenced SOX2 in freshly derived glioblastoma tumor-initiating cells (TICs). Our results indicate that SOX2 silenced glioblastoma TICs, despite the many mutations they have accumulated, stop proliferating and lose tumorigenicity in immunodeficient mice. SOX2 is then also fundamental for maintenance of the self-renewal capacity of neural stem cells when they have acquired cancer properties. SOX2, or its immediate downstream effectors, would then be an ideal target for glioblastoma therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria.

              Tumor cells with stem cell-like properties can be cultured from human glioblastomas by using conditions that select for the expansion of neural stem cells. We generated cell lines from glioblastoma specimens with the goal to obtain model systems for glioma stem cell biology. Unsupervised analysis of the expression profiles of nine cell lines established under neural stem cell conditions yielded two distinct clusters. Four cell lines were characterized by the expression of neurodevelopmental genes. They showed a multipotent differentiation profile along neuronal, astroglial and oligodendroglial lineages, grew spherically in vitro, expressed CD133 and formed highly invasive tumors in vivo. The other five cell lines shared expression signatures enriched for extracellular matrix-related genes, had a more restricted differentiation capacity, contained no or fewer CD133+ cells, grew semiadherent or adherent in vitro and displayed reduced tumorigenicity and invasion in vivo. Our findings show that stable, multipotent glioblastoma cell lines with a full stem-like phenotype express neurodevelopmental genes as a distinctive feature, which may offer therapeutic targeting opportunities. The generation of another distinct cluster of cell lines showing similarly homogeneous profiling but restricted stem cell properties suggests that different phenotypes exist, each of which may lead to the typical appearance of glioblastoma.
                Bookmark

                Author and article information

                Contributors
                +48 42 675 76 11 , +48 675 76 29 , monika.witusik-perkowska@umed.lodz.pl , monikawitusik@interia.pl
                Journal
                J Neurooncol
                Journal of Neuro-Oncology
                Springer US (Boston )
                0167-594X
                1573-7373
                29 August 2010
                29 August 2010
                May 2011
                : 102
                : 3
                : 395-407
                Affiliations
                [1 ]Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Czechoslowacka 8/10 str, 92-216 Lodz, Poland
                [2 ]Department of Neurosurgery, Medical University of Lodz, Kopcinskiego 22 str, 90-153 Lodz, Poland
                [3 ]Department of Pathomorphology, Medical University of Lodz, Czechoslowacka 8/10 str, 92-216 Lodz, Poland
                [4 ]Department of Neurosurgery, Polish Mother’s Memorial Hospital Research Institute, Rzgowska 281/289 str, 93-338 Lodz, Poland
                [5 ]Department of Neurosurgery, Copernicus Hospital in Lodz, Pabianicka 62 str, 93-513 Lodz, Poland
                [6 ]National Creutzfeldt–Jakob Disease Surveillance Unit, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU UK
                Article
                352
                10.1007/s11060-010-0352-0
                3089721
                20803305
                eb21afc2-9dac-4659-ae7f-f6c6ce9b5306
                © The Author(s) 2010
                History
                : 30 March 2010
                : 9 August 2010
                Categories
                Laboratory Investigation - Human/Animal Tissue
                Custom metadata
                © Springer Science+Business Media, LLC. 2011

                Oncology & Radiotherapy
                glioblastoma,cell cultures,egfr amplification,egfrviii,spheroids
                Oncology & Radiotherapy
                glioblastoma, cell cultures, egfr amplification, egfrviii, spheroids

                Comments

                Comment on this article